Careers
Contact
Menu
Skip to content
ABOUT US
OUR MISSION
OUR LEADERSHIP
OUR TEAM
BOARD OF DIRECTORS
SCIENTIFIC ADVISORS
PLATFORMS
SYNTHETIC BIOLOGY
CAR-TCR
GENE EDITING
IMMUNO ONCOLOGY ANTIBODIES
Nucleic acid drugs
PIPELINE
PARTNERSHIPS
JOINT VENTURES
COLLABORATIONS
WHOLLY-OWNED SORRENTO SUBSIDIA
NEWS
INVESTORS
EVENTS AND PRESENTATIONS
STOCK INFORMATION
CORPORATE GOVERNANCE
SEC DOCUMENTS
SERVICE
CONTACT
Chinese
English
News Releases
Good news! Dr. Dai Hongjiu, the CEO of KAEDI, has been selected as the
03 15,2024
Clinical trial of the world's first innovative dual-targeted CAR-T cell drug
03 15,2024
The clinical kickoff meeting of KD-496 CAR-T of KAEDI was successfully held
11 27,2023
Dr.HongjiuDai,CEO of KAEDI, was invited to attend the 2023 GoBroad Science Forum
08 02,2023
銆�2023 Solid Tumor Cell Therapy Pine Meeting銆慉 complete success
07 21,2023
KAEDI and PORTON deepened their strategic cooperation
07 21,2023
KAEDI and Kactus Biosystems reached a strategic cooperation
07 21,2023
2023 Solid Tumor Cell Therapy Pine and Cypress Conference will be grandly coming
07 21,2023
Emily, the first girl in the world to be cured by CAR-T therapy
05 15,2023
2023 KAEDI Medical Group building expansion
04 27,2023
NKG2D-CAR-T (KD-025) is a new breakthrough in the treatment of gastric cancer
05 09,2023
KAEDI held the 2022 annual honoring conference
03 29,2023
MENU
ABOUT US
OUR MISSION
OUR LEADERSHIP
OUR TEAM
BOARD OF DIRECTORS
SCIENTIFIC ADVISORS
PLATFORMS
SYNTHETIC BIOLOGY
CAR-TCR
GENE EDITING
IMMUNO ONCOLOGY ANTIBODIES
Nucleic acid drugs
PIPELINE
PARTNERSHIPS
JOINT VENTURES
COLLABORATIONS
WHOLLY-OWNED SORRENTO SUBSIDIA
NEWS
INVESTORS
EVENTS AND PRESENTATIONS
STOCK INFORMATION
CORPORATE GOVERNANCE
SEC DOCUMENTS
SERVICE
CONTACT